biostudies-literatureUnknown23(1)Nguyen VC<h4>Background</h4>Late detection of hepatocellular carcinoma (HCC) results in an overall 5-year survival rate of less than 16%. Liquid biopsy (LB) assays based on detecting circulating tumor DNA (ctDNA) might provide an opportunity to detect HCC early noninvasively. Increasing evidence indicates that ctDNA detection using mutation-based assays is significantly challenged by the abundance of white blood cell-derived mutations, non-tumor tissue-derived somatic mutations in plasma, and the mutational tumor heterogeneity.<h4>Methods</h4>Here, we employed concurrent analysis of cancer-related mutations, and their fragment length profiles to differentiate mutations from different sources. To distinguish persons with HCC (PwHCC) from healthy participants, we built a classification model using thBMC cancer233https://www.ebi.ac.uk/biostudies/studies/S-EPMC10009971biostudies-literatureFragment length profiles of cancer mutations enhance detection of circulating tumor DNA in patients with early-stage hepatocellular carcinoma.PMC10009971Nguyen HHTNguyen TDPham TTTHuynh LAKPhu DTBNguyen THNguyen CMTruong DKNguyen VCGiang HPhan THHo TDPhan MDTran LSNguyen QBKim VVNguyen BTDo TTTran TTNguyen HNTran VUBach HTPhan BHHTran TTTNguyen QTDuong MLPham TANguyen TNVfalseFragment length profiles of cancer mutations enhance detection of circulating tumor DNA in patients with early-stage hepatocellular carcinoma.<h4>Background</h4>Late detection of hepatocellular carcinoma (HCC) results in an overall 5-year survival rate of less than 16%. Liquid biopsy (LB) assays based on detecting circulating tumor DNA (ctDNA) might provide an opportunity to detect HCC early noninvasively. Increasing evidence indicates that ctDNA detection using mutation-based assays is significantly challenged by the abundance of white blood cell-derived mutations, non-tumor tissue-derived somatic mutations in plasma, and the mutational tumor heterogeneity.<h4>Methods</h4>Here, we employed concurrent analysis of cancer-related mutations, and their fragment length profiles to differentiate mutations from different sources. To distinguish persons with HCC (PwHCC) from healthy participants, we built a classification model using th2023-01-01T00:00:00Z2023 Mar2025-05-29T19:43:44.866Z2025-04-05T13:33:03.086ZS-EPMC100099713691506910.1186/s12885-023-10681-0